What's the Outlook for BioNTech Stock?

Since its IPO last October, the stock price of COVID-19 vaccine and oncological treatment developer BioNTech (NASDAQ: BNTX) was up by more than 489% as of market close on Oct. 27. That's phenomenal considering the S&P 500 only gained 15% during the same period.

Now that the COVID-19 vaccine race is approaching the stage where some competitors could cross the finish line, investors are beginning to demand results from developers in the biotech sector. Fortunately, BioNTech remains one of the best coronavirus stocks in terms of vaccine potential and room for its stock to run even more. 

Image Source: Getty Images.

Continue reading

Source Fool.com